These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy. Fletcher SA; Pallauf M; Watts EK; Lombardo KA; Campbell JA; Rezaee ME; Rouprêt M; Boorjian SA; Potretzke AM; Roshandel MR; Ploussard G; Djaladat H; Ghoreifi A; Mari A; Campi R; Khene ZE; Raman JD; Kikuchi E; Rink M; Abdollah F; Boormans JL; Fujita K; D'Andrea D; Soria F; Breda A; Hoffman-Censits J; McConkey DJ; Shariat SF; Pradere B; Singla N Eur Urol Oncol; 2024 Oct; 7(5):1061-1068. PubMed ID: 38262800 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy Benefits Survival in High-Grade Upper Tract Urothelial Carcinoma: A Propensity Score-Based Analysis. Chen L; Ou Z; Wang R; Zhang M; He W; Zhang J; Zu X; Yi L; Xu R; Jiang S; Qi L; Wang L Ann Surg Oncol; 2020 Apr; 27(4):1297-1303. PubMed ID: 31853757 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. Quhal F; Mori K; Sari Motlagh R; Laukhtina E; Pradere B; Rouprêt M; Necchi A; Moschini M; Shariat SF Int J Clin Oncol; 2020 Jun; 25(6):1037-1054. PubMed ID: 32206939 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. Liao RS; Gupta M; Schwen ZR; Patel HD; Kates M; Johnson MH; Hahn NM; McConkey D; Bivalacqua TJ; Pierorazio PM J Urol; 2018 Jul; 200(1):68-73. PubMed ID: 29307680 [TBL] [Abstract][Full Text] [Related]
6. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677 [TBL] [Abstract][Full Text] [Related]
7. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254 [TBL] [Abstract][Full Text] [Related]
8. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study. Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Lynch SP; Shen Y; Kamat A; Grossman HB; Shah JB; Millikan RE; Dinney CP; Siefker-Radtke A Eur Urol; 2013 Aug; 64(2):307-13. PubMed ID: 22564397 [TBL] [Abstract][Full Text] [Related]
10. Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Kim JK; Moon KC; Jeong CW; Kwak C; Kim HH; Ku JH Urol Oncol; 2017 Jul; 35(7):458.e9-458.e15. PubMed ID: 28347659 [TBL] [Abstract][Full Text] [Related]